MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will be participating in the 2024 Cell & Gene Meeting on the Mesa, scheduled for October 7-9 at the Arizona Biltmore in Phoenix, AZ. Dr. Shankar Musunuri, the company’s Chairman and CEO, will present on Monday, October 7, 2024, at 1:30 p.m. MST in Ballroom F.
During his presentation, Dr. Musunuri will discuss Ocugen’s pioneering gene therapy platform. His talk will focus on the OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa, the OCU410 Phase 2 ArMaDa trial for geographic atrophy, and the OCU410ST Phase 1/2 GARDian trial for Stargardt disease. OCU400 is currently dosing in its Phase 3 trial, with approval targets set for 2026.
Dr. Musunuri remarked, “The Cell & Gene Meeting on the Mesa convenes industry decision-makers to address all aspects of translating cutting-edge science into effective treatment options—especially where no treatment options exist.”
In addition to Dr. Musunuri’s session, Ocugen’s executive team will participate in one-on-one meetings to discuss the company’s strategic and clinical developments. Virtual attendance is available, with a livestream and on-demand viewing options for conference sessions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.